Type of Study: Clinical Trial

Sponsor / Support: LACOG, Janssen

Primary Objectives: We aim to assess the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced or metastatic prostate cancer which ADT was indicated.

Design: This is a phase II, open label, randomized trial

Sample Size: 126 patients

Principal Investigator: Fernando Cotait Maluf

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT02867020